From Wikipedia, the free encyclopedia
Jump to: navigation, search

Dynepo is a form of pharmaceutical erythropoietin (EPO) under development as a pharmaceutical product by Shire Pharmaceuticals. The first development steps were performed by HMR and Aventis. Aventis obtained the license in Europe in 2002. The company expects to launch the product in Europe in 2006, although patents held by the American biotechnology company Amgen, Inc. may preclude its sale in the United States.

EPO is a natural human hormone that stimulates formation of red blood cells. It is made via recombinant DNA technology. Pharmaceutical EPO is used to treat anemia, but has also been used by doping athletes to improve their aerobic performance and stamina.

Unlike existing forms of pharmaceutical EPO manufactured in cultured animal cells, Dynepo is to be made in cultured human cells. It is therefore expected to have an authentic human form of sialic acid and other oligosaccharide residues. This characteristic may make it a longer-acting product than existing brands, but clinical data have not yet been made public. It should also make Dynepo undetectable in the existing urine test for EPO used to detect doping by athletes.

On July 1, 2009, professional cycling team Silence-Lotto announced that Thomas Dekker was tested positive for dynepo on a test taken on December 24, 2007, while Dekker was riding for Rabobank.


Dynepo EPAR (European Public Assessment Report), PDF format , credit European Medicines Agency